TNGX Tango Therapeutics, Inc.
Q3 2025 10-Q
Tango Therapeutics, Inc. (TNGX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • Newly added risk: Ongoing U.S. government shutdown since Sept 30, 2025 impacting FDA, SEC operations and potentially delaying regulatory reviews
- • Most materially updated risk: Executive Orders 14273 and 14297 direct aggressive federal drug pricing policies, potentially affecting pricing, approvals, and market access
Quarterly Financial SummaryXBRL
Revenue
$54M
Net Income
$16M
Operating Margin
26.2%
Net Margin
29.5%
ROE
9.9%
Total Assets
$210M
Source: XBRL data from Tango Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tango Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.